Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials

Published:2019-11-26 Issue:5 Volume:45 Page:887-901
ISSN:0893-133X
Container-title:Neuropsychopharmacology
language:en
Short-container-title:Neuropsychopharmacol.

Author:

Tani Hideaki,Takasu Shotaro,Uchida Hiroyuki^ORCID,Suzuki Takefumi^ORCID,Mimura Masaru,Takeuchi Hiroyoshi^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Pharmacology

Link

http://www.nature.com/articles/s41386-019-0573-7.pdf

Reference84 articles.

1. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379:2063–71.

2. Goff DC, Falkai P, Fleischhacker WW, Girgis RR, Kahn RM, Uchida H, et al. The long-term effects of antipsychotic medication on clinical course in schizophrenia. Am J Psychiatry. 2017;174:840–9.

3. Takeuchi H, Kantor N, Sanches M, Fervaha G, Agid O, Remington G. One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis. Br J Psychiatry. 2017;211:137–43.

4. Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol. 1997;17:194–201.

5. Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, et al. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophr Bull. 2013;39:564–74.

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The myth of minimum effective dose in antipsychotic treatment for patients with remitted psychosis;European Neuropsychopharmacology;2024-11

2. Conceptualization and characterization of “primary” and “secondary” cognitive impairment in schizophrenia;Psychiatry Research;2024-10

3. Monitoring momentary subjective well-being and psychotic experiences during antipsychotic dose reduction: Two single-case time series experience sampling method pilot study.;Psychiatric Rehabilitation Journal;2024-07-25

4. Changing vistas of psychosis and antipsychotic drug dosing toward personalized management of antipsychotics in clinical practice.;Psychiatric Rehabilitation Journal;2024-04-22

5. Peculiarities of personalized selection of antipsychotic drugs for schizophrenia treatment;Medicni perspektivi;2024-04-01